As of June 26, 2025, Applied Genetic Technologies Corp (AGTC) reports a ROE (Return on Equity) of -233.89%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Applied Genetic Technologies Corp's ROE (Return on Equity)
Over recent years, Applied Genetic Technologies Corp's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-06-30 | -233.89% |
| 2021-06-30 | -67.39% |
| 2020-06-30 | -64.63% |
| 2019-06-30 | -2.55% |
| 2018-06-30 | -21.47% |
This slight downward trend highlights how Applied Genetic Technologies Corp manages its efficiency in generating profits from shareholders' equity over time.
Comparing Applied Genetic Technologies Corp's ROE (Return on Equity) to Peers
To better understand Applied Genetic Technologies Corp's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Applied Genetic Technologies Corp (AGTC) | -233.89% |
| IMV Inc (IMV.TO) | 575.45% |
| Checkpoint Therapeutics Inc (CKPT) | 445.47% |
| Abbvie Inc (ABBV) | 128.66% |
| Amgen Inc (AMGN) | 69.59% |
| Regeneron Pharmaceuticals Inc (REGN) | 15.03% |
Compared to its competitors, Applied Genetic Technologies Corp's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.